Description of event:
3rd Annual Pharmacovigilance 2012
“Ensuring safer
drugs to market by analyzing latest developments in pharmacovigilance,
drug safety and risk
management"
31st August 2012, Hyatt Regency, Mumbai, India
The
Pharmaceutical industry in India is valued at Rs. 90,000 Crore and is growing at the rate of 12 – 14 % per annum. Exports are growing at 25 % Compound Annual Growth Rate (CAGR) every year. The total export of pharma products is to the extent of Rs. 40,000 Crore. India is now being recognized as the ‘Global pharmacy of Generic
Drugs’ & has distinction of providing generic quality
drugs at affordable cost. India is also emerging rapidly as a hub of Global
Clinical trials & a destination for
Drug Discovery & Development. Indian
pharmaceutical industry is said to reach $20 billion by 2015, making it one of the world's top 10 pharmaceuticals markets. There is a surfeit of
drug brands more than 6000 licensed
drug manufactures and over 60,000 branded formulations. All medicines have potential risk as well as benefits.
In 2011 India exported USD 10.3 billion worth of pharma products, registering 17.5 per cent growth over a year before. India's largest export destination for pharma products is still the USA, followed by the UK, Germany, South Africa and Russia. By 2020, the size of the global
pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey
More
clinical research activities being conducted in India, there is an immense need to understand the importance of pharmacovigilance and how it impacts the life cycle of the product. A good pharmacovigilance will easily identify the risk factors in the shortest time so that the harmful effects can be avoided or minimized.
Pharmacovigilance 2012 will discuss the pressing concerns confronted with regard to
drug safety, addressing the risks, time line, budget constrains, effectively tackling key challenges, overcoming trial agreement and site contract negotiation hurdles. Top
pharmaceutical, biotech, and regulatory representatives will discuss the
current complexities and controversies in pharmacovigilance and risk
management throughout all phases of development
The Conference will bring together top
pharmaceutical,
biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection,
analysis and prevention of adverse
drug reactions. It will be studied with the help of case studies and industry experiences.
Pharmacovigilance 2012 is the latest in Virtue Insight’s series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, 3rd Annual Pharmacovigilance 2012 will provide an important platform for pharmacovigilance stakeholders from India to discuss and share best practices in expediting pharmacovigilance development in India.
It gives me great pleasure in welcoming all of you to the virtue insight’s 3rd Annual Pharmacovigilance 2012. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.
KEY THEMES DISCUSSED AT THIS CONFERENCE:-
Exploiting the latest technologies, methodologies and Introducing pharmacy automations on work practices of Pharmacovigilance
Keeping abreast of the changes impacting the
drug safety industry to ensure the pharmacovigilance strategies are robust and geared to
compliance
Recent successful strategies and business models to bring out new medicines
How will PV activities change with
Clinical Trial Transformation Initiative?
Identifying essential antidote requirements and learn to implement best practices in
drug safety and surveillance
Exploiting the pharmacy automations and technologies for enhancement of medication safety
Stay ahead of computing and electronic communications in pharmacovigilance
Latest developments in pharmacovigilance,
drug safety and risk
management to ensure safer
drugs to market
Establishing the importance of pharmacovigilance for the safety of the patient
Determining the steps and strategies for enhancing quality in healthcare
Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
Analyzing the information on
current industry projects and trends
Identifying the latest regulatory framework for pharmacovigilance
WHO SHOULD ATTEND:-
VP’s, Directors,
CRO’s, Heads and Managers of:
Pharmacovigilance Strategy
Drug Safety/Risk
Management
Information and
Clinical Data Management
Clinical Research
Research & Development
Product Safety/Assurance Assessment
Patient Safety & Outcomes Research &
Data Analysis
Epidemiology project
management
Regulatory Affairs and
Compliance
Sales & Marketing
WHY SHOULD YOU ATTEND:-
3rd Annual Pharmacovigilance 2012- “Ensuring safer
drugs to market by analyzing latest developments in pharmacovigilance,
drug safety and risk
management ”
Get more from the event, with a broader
scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
Contact us:
Virtue Insight,
Plot No – 07 – 2nd Floor
Ekambaram Industrial Estate
Alapakkam, Porur
Chennai – 600 116
India
Email: info@virtueinsight.com